Search
Search Results
-
Association of Drug–Disease Interactions with Mortality or Readmission in Hospitalised Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis
Background and ObjectiveMultimorbidity is common in hospitalised adults who are at increased risk of inappropriate prescribing including drug–disease...
-
Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions
BackgroundDrug toxicity does not affect patients equally; the toxicity may only exert in patients who possess certain attributes of susceptibility to...
-
Potential Drug–Drug Interactions Among Hospitalised Elderly Patients in Northern Sri Lanka, A Lower Middle-Income Country: A Retrospective Analysis
Background and ObjectivesElderly individuals are more vulnerable to potential drug–drug interactions (pDDIs) as age-related physiological changes,...
-
Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
Background and ObjectiveSpinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by insufficient levels of survival motor neuron...
-
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study
BackgroundThe increasing number of direct-acting antiviral (DAA) regimens along with limited number of subjects and co-medications involved in...
-
Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil
Background and ObjectiveEarly investigations into drug–drug interactions (DDIs) involving cytochrome P450 2C8 (CYP2C8) have highlighted the...
-
Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers
Background and ObjectiveTucatinib is approved for treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer....
-
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir
Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease that is used as an...
-
Assessment of potential drug–drug interaction knowledge, attitude, and practice among Egyptian hospital and community pharmacists: a cross-sectional multicenter study
BackgroundPharmacists have an important role in preventing prescribing errors and providing appropriate information. They can detect potential...
-
Clinical significance of potential drug–drug interactions in older adults with psychiatric disorders: a retrospective study
BackgroundPolypharmacy increases the risk of potential drug–drug interactions (pDDIs). This retrospective analysis was conducted to detect pDDIs and...
-
Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents
The treatment of patients infected with the hepatitis C virus (HCV) has been revolutionised by the development of direct-acting antiviral agents...
-
Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study
IntroductionThe objective was to characterize real-world outcomes of drug–drug interactions (DDIs) between antiretrovirals (ARVs) and other drugs,...
-
Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report
BackgroundResponse to antidepressant therapy is highly variable among individuals. Pharmacogenomic (PGx) testing presents an opportunity to guide...
-
Methodological Considerations on the Use of Cohort Designs in Drug-Drug Interaction Studies in Pharmacoepidemiology
Purpose of ReviewThe evidence regarding the clinical effects of drug-drug interactions (DDIs) is scarce and limited. Pharmacoepidemiologic studies...
-
Prediction of Drug–Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model
Background and ObjectiveA physiologically based pharmacokinetic (PBPK) modeling approach for esketamine and its metabolite noresketamine after...
-
Timing Matters: A Machine Learning Method for the Prioritization of Drug–Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure
IntroductionCurrent drug–drug interaction (DDI) detection methods often miss the aspect of temporal plausibility, leading to false-positive...
-
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist
Background and objectiveCilofexor is a selective farnesoid X receptor (FXR) agonist in development for the treatment of nonalcoholic steatohepatitis...
